EN ID

EPMT

ENSEVAL

Integrated Healthcare Distribution Solutions

Enseval for a Healthier Indonesia

ENSEVAL

Preserving Health, Precisely and Reliably

Maintaining Quality, Distributing Hope

ENSEVAL

Access to Healthcare for a Better Life

Efficient, integrated, bringing health closer to everyone

ABOUT US

More Than 50 Years of Excellence as a Healthcare Solutions

Enseval plays a crucial role in the Indonesian healthcare sector by ensuring the availability and accessibility of essential pharmaceutical and consumer health products nationwide.

Distribution Center

72

Branches in 34 Provinces

>1500

Delivery Fleet

>200K

Customers

Our Nationwide Network

Reaching the Archipelago, Connecting Healthcare

Driving Your Business Forward

Our Comprehensive Business Solutions

Enseval provides integrated solutions to enhance efficiency, reliability, and growth. From distribution and logistics to healthcare and marketing, we help drive your business forward.

See All

Distribution & Logistic

Comprehensive Distribution Services and Efficient Quality Supply Chain Management.

Raw Materials

Trusted Raw Material Solutions for Health and Food Industries.

Medical Devices and Diagnostics

Comprehensive Solutions in Marketing, Locally Manufactured Devices, and Hemodialysis Services.

Advanced Digital Solutions

Innovating Digital Solutions for Healthcare Logistics.

Healthcare Services

Easy & Trusted Healthcare Access.

Integrated Business Support Services

Empowering Growth through Strategic Solutions.

Empowering Supply Chains

With end-to-end total logistics solution

Distribution & Logistics

Raw materials

Digital Order Management

Medical Equipment

Medical Device Manufacturing

Hemodialysis Services

Logistic Total Solutions

Clinic & Pharmacy Chain

Latest News

See All

30 Oct 2026

NET SALES OF ENSEVAL GROW BY 10.93% IN THE THIRD QUARTER OF 2026

PT Enseval Putera Megatrading Tbk ("the Company") recorded net sales of Rp27,104.22 billion in the third quarter of 2026, based on the Company’s unaudited consolidated financial statements and its subsidiaries for the period ended September 30, 2026. This figure represents a 10.93% increase compared to net sales of Rp24,434.73 billion in the third quarter of 2025, reflecting the continuous growth of the Company's business activities.